Kimia Therapeutics
This role leads the in silico components of Kimia Therapeutics' ATLAS platform, integrating high-throughput chemistry and biology with advanced computational methods. The position is responsible for building the software and data infrastructure that powers the company’s drug discovery engine in oncology and immune disorders. Reporting to the CTO, the leader will shape and execute the digital strategy, working closely with chemistry and biology counterparts. The role operates in a startup environment with significant influence on both the scientific platform and company culture.
Headquarters
Berkeley, California, United States
Company Size
11-50 employees
Founded
2023
Kimia is a drug discovery company building a chemical atlas to treat human disease. Its ATLAS platform combines Active® Learning, automated synthesis, high‑throughput screening and machine learning to map relationships between chemical structure and protein function at high resolution and define druggable space. Through iterative generative chemistry workflows, Kimia designs, synthesizes, and tests novel molecules to uncover therapeutic targets and candidate drugs. The integrated automation + ML approach accelerates discovery and expands accessible chemical matter for generative drug design.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Kimia Therapeutics.
Kimia Therapeutics didn’t post a salary, so this is our estimate from similar listings.
Fierce Biotech Fundraising Tracker '23: Carmot spinoff Kimia raises $55M; Lassen fuels for fibro-inflammatory mission
Dec 20, 2023